MX2014005544A - Neurotoxinas que exhiben actividad biologica acortada. - Google Patents

Neurotoxinas que exhiben actividad biologica acortada.

Info

Publication number
MX2014005544A
MX2014005544A MX2014005544A MX2014005544A MX2014005544A MX 2014005544 A MX2014005544 A MX 2014005544A MX 2014005544 A MX2014005544 A MX 2014005544A MX 2014005544 A MX2014005544 A MX 2014005544A MX 2014005544 A MX2014005544 A MX 2014005544A
Authority
MX
Mexico
Prior art keywords
polypeptides
present
polynucleotide
medicaments
ligase
Prior art date
Application number
MX2014005544A
Other languages
English (en)
Other versions
MX351012B (es
Inventor
Michael Schmidt
Jürgen FREVERT
Fred Hofmann
Gerhard Groer
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48288558&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014005544(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of MX2014005544A publication Critical patent/MX2014005544A/es
Publication of MX351012B publication Critical patent/MX351012B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere al campo farmacéutico. Específicamente, contempla un polinucleótido que codifica para un polipéptido de neurotoxina que exhibe una duración reducida del efecto biológico en un sujeto, en donde el polipéptido comprende al menos un motivo de reconocimiento de ligasa E3 de la cadena ligera, en donde el motivo de reconocimiento de ligasa E3 es de preferencia un motivo de unión para la ligasa E3 MDM2. La invención se refiere además a polipéptidos codificados por el polinucleátido de la invención así como a polipéptidos que comprenden una o más sustituciones de aminoácido. La presente invención también abarca vectores y células hospederas que comprenden el polinucleótido, polipéptidos codificados por el mismo y anticuerpos que se unen específicamente a los polipéptidos. Más aún, la invención se refiere a medicamentos que comprenden los polinucleátidos y polipéptidos, así como a aplicaciones terapéuticas específicas de los mismos. Además, la presente invención contempla métodos para la elaboración de los polipéptidos y medicamentos.
MX2014005544A 2011-11-09 2012-11-08 Neurotoxinas que exhiben actividad biologica acortada. MX351012B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161628911P 2011-11-09 2011-11-09
EP11188440 2011-11-09
US201261659137P 2012-06-13 2012-06-13
EP12171801 2012-06-13
PCT/EP2012/072158 WO2013068476A1 (en) 2011-11-09 2012-11-08 Neurotoxins exhibiting shortened biological activity

Publications (2)

Publication Number Publication Date
MX2014005544A true MX2014005544A (es) 2014-05-30
MX351012B MX351012B (es) 2017-09-28

Family

ID=48288558

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014005544A MX351012B (es) 2011-11-09 2012-11-08 Neurotoxinas que exhiben actividad biologica acortada.

Country Status (18)

Country Link
US (1) US9809809B2 (es)
EP (1) EP2776457B1 (es)
JP (1) JP6162135B2 (es)
KR (1) KR20150000468A (es)
CN (1) CN103974973A (es)
AR (1) AR089655A1 (es)
AU (1) AU2012334080B2 (es)
BR (1) BR112014011137A2 (es)
CA (1) CA2855173A1 (es)
CL (1) CL2014001217A1 (es)
ES (1) ES2638333T3 (es)
HK (1) HK1199890A1 (es)
IL (1) IL232508B (es)
MX (1) MX351012B (es)
RU (1) RU2646110C2 (es)
SG (1) SG11201402131TA (es)
TW (1) TWI583792B (es)
WO (1) WO2013068476A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140377248A1 (en) * 2011-12-23 2014-12-25 Merz Pharma Gmbh & Co. Kgaa Method for the manufacturing of di-chain proteins for use in humans
RU2673910C2 (ru) * 2012-11-21 2018-12-03 Ипсен Байоинновейшн Лимитед Способ производства протеолитически процессированного полипептида
GB201312317D0 (en) * 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
PL2952205T3 (pl) 2014-06-06 2018-01-31 Kleiner Fisman Galit Toksyna botulinowa do zastosowania do leczenia paratonii
US20170128551A1 (en) * 2014-06-13 2017-05-11 Klaus Fink Novel uses of recombinant clostridial neurotoxins with decreased duration of effect
WO2015188945A1 (en) 2014-06-13 2015-12-17 Merz Pharma Gmbh & Co. Kgaa Novel uses of recombinant clostridial neurotoxins with decreased duration of effect
EP3154571A1 (en) 2014-06-13 2017-04-19 Merz Pharma GmbH & Co. KGaA Use of recombinant clostridial neurotoxins for the treatment of patients having certain muscle-related disorders
US20170119863A1 (en) * 2014-06-13 2017-05-04 Merz Pharma Gmbh & Co. Kgaa Novel uses of recombinant clostridial neurotoxins with decreased duration of effect
ES2837699T3 (es) * 2014-12-19 2021-07-01 Merz Pharma Gmbh & Co Kgaa Medios y métodos para la determinación de la actividad biológica de BoNT/E en células
SG11201705019PA (en) 2014-12-23 2017-07-28 Merz Pharma Gmbh & Co Kgaa Botulinum toxin prefilled container
DK3242884T3 (da) 2015-01-09 2021-04-19 Ipsen Bioinnovation Ltd Kationiske neurotoksiner
US9765117B2 (en) 2015-08-24 2017-09-19 Romek Figa Peptides for treating cancer
WO2017063743A1 (en) 2015-10-14 2017-04-20 Merz Pharma Gmbh & Co. Kgaa Improvements to ultrasound-based therapy of photoaged tissue
CA3010146A1 (en) 2016-03-02 2017-09-08 Merz Pharma Gmbh & Co. Kgaa Composition comprising botulinum toxin
TWI737742B (zh) 2016-06-22 2021-09-01 德商梅茲製藥有限兩合公司 肉毒桿菌毒素的預填充式注射器系統、具有其之套組以及其之使用
EP3290437A1 (en) 2016-08-31 2018-03-07 Merz Pharma GmbH & Co. KGaA Novel recombinant clostridial neurotoxins with decreased duration of effect
CN106432423B (zh) * 2016-09-21 2019-05-10 北京大学深圳研究生院 一种α-螺旋多肽及其用途
EP3312193A1 (en) 2016-10-19 2018-04-25 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with accelerated onset of effect
KR20190126894A (ko) 2017-03-22 2019-11-12 본티, 인크. 치료법에서 사용하기 위한 보툴리눔 신경독소
US11952601B2 (en) 2017-06-20 2024-04-09 Merz Pharma Gmbh & Co. Kgaa Recombinant botulinum toxin with increased duration of effect
EP3649143B1 (en) * 2017-07-06 2022-08-31 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with increased duration of effect
US11279734B2 (en) 2017-12-01 2022-03-22 Massachusetts Institute Of Technology Solution-phase affinity selection of inhibitors from combinatorial peptide libraries
WO2019158745A1 (de) * 2018-02-16 2019-08-22 Bontana Therapies Gmbh Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung
CN112135840B (zh) * 2018-03-13 2024-01-23 斯米维特公司 与破伤风神经毒素结合的单域抗体
GB201815844D0 (en) * 2018-09-28 2018-11-14 Ipsen Biopharm Ltd Therapeutic & comestic uses of botulinum neurotoxin serotype e
CN109666683B (zh) * 2019-02-27 2021-10-29 昆明理工大学 乙酰辅酶A乙酰转移酶基因RKAcaT2及其应用
CN110721314B (zh) * 2019-10-11 2022-11-29 江苏恒泰生物科技有限公司 一种抗肿瘤纳米药物及其制备方法
SE2050326A1 (en) * 2020-03-25 2021-06-29 Jonathan Davies Engineered botulinum neurotoxin serotype E
CN111763663B (zh) * 2020-07-09 2022-04-15 昆明理工大学 一种天麻葡糖基转移酶基因及应用
CN112410321B (zh) * 2020-11-26 2022-01-28 昆明理工大学 一种β-葡萄糖苷酶Ttbgl3及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69738754D1 (de) * 1996-07-05 2008-07-17 Cancer Rec Tech Ltd Hemmer der interaktion zwischen p53 und mdm2
GB9708092D0 (en) * 1997-04-22 1997-06-11 Univ Dundee Materials and methods relating to inhibiting the interaction of p53 and mdm2
GB9708089D0 (en) 1997-04-22 1997-06-11 Univ Dundee Materials and methods relating to stabilising substances in cells
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US6678651B2 (en) * 2000-09-15 2004-01-13 Mindspeed Technologies, Inc. Short-term enhancement in CELP speech coding
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
AU2005274822B2 (en) 2004-07-26 2008-10-30 Merz Pharma Gmbh & Co. Kgaa Therapeutic composition with a botulinum neurotoxin
WO2008106507A2 (en) * 2007-02-27 2008-09-04 University Of South Florida Mdm2/mdmx inhibitor peptide
CA2680741A1 (en) * 2007-03-22 2009-01-15 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
WO2008157374A1 (en) * 2007-06-13 2008-12-24 The United States Of America, As Represented By The Secretrary Of Agriculture High-affinity monoclonal antibodies for botulinum toxin type a
WO2009014854A1 (en) * 2007-07-26 2009-01-29 Allergan, Inc. Methods of activiting clostridial toxins
FR2924721B1 (fr) 2007-12-10 2010-02-26 Cytomics Systems Procede de criblage d'agents modulant l'activite de l'ubiquitine ligase mdm2 et moyens destines a la mise en oeuvre dudit procede
US8343743B2 (en) * 2008-06-10 2013-01-01 Synaptic Research, Llc Designer ubiquitin ligases having a non-cleavable SNAP25 domain and E3-ligase domain
US20100278826A1 (en) * 2008-06-10 2010-11-04 Shoemaker Charles B Designer Ubiquitin Ligases For Regulation Of Intracellular Pathogenic Proteins
RU2582266C2 (ru) * 2009-07-02 2016-04-20 Мерц Фарма Гмбх Унд Ко. Кгаа Нейротоксины, проявляющие сокращенную биологическую активность

Also Published As

Publication number Publication date
CN103974973A (zh) 2014-08-06
AU2012334080B2 (en) 2016-12-15
AR089655A1 (es) 2014-09-10
US9809809B2 (en) 2017-11-07
JP2014533945A (ja) 2014-12-18
WO2013068476A1 (en) 2013-05-16
TWI583792B (zh) 2017-05-21
HK1199890A1 (en) 2015-07-24
TW201326390A (zh) 2013-07-01
EP2776457B1 (en) 2017-08-02
BR112014011137A2 (pt) 2018-06-12
SG11201402131TA (en) 2014-08-28
ES2638333T3 (es) 2017-10-19
IL232508B (en) 2018-06-28
CA2855173A1 (en) 2013-05-16
US20140308267A1 (en) 2014-10-16
IL232508A0 (en) 2014-06-30
RU2014123060A (ru) 2015-12-20
EP2776457A1 (en) 2014-09-17
CL2014001217A1 (es) 2014-10-10
RU2646110C2 (ru) 2018-03-01
JP6162135B2 (ja) 2017-07-12
MX351012B (es) 2017-09-28
KR20150000468A (ko) 2015-01-02
AU2012334080A1 (en) 2014-05-15

Similar Documents

Publication Publication Date Title
MX351012B (es) Neurotoxinas que exhiben actividad biologica acortada.
MX352265B (es) Neurotoxinas que exhiben actividad biologica acortada.
EA201101553A1 (ru) Полипептид, деградирующий углеводы, и его применения
MX371442B (es) VARIANTE DE LA REGION FC ESPECIFICA PARA FCyRIIB.
EA201201126A1 (ru) Полипептид, обладающий активностью целлобиогидролазы, и его применение
MX348071B (es) Variantes de fc.
MX359953B (es) Ácido nucleico que comprende o que codifica un tallo-rizo de histona y una secuencia poli (a) o una señal de poliadenilación para incrementar la expresión de una proteína terapéutica codificada.
IN2014CN00414A (es)
PH12014502767A1 (en) Interleukin-2 fusion proteins and uses thereof
UA117218C2 (uk) Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
NZ603570A (en) Biological materials related to her3
MX353067B (es) Composiciones de peptidos de glp-1 y preparaciones de las mismas.
CA2818990A1 (en) Designed repeat proteins binding to serum albumin
EA201300060A1 (ru) Полипептид, обладающий или содействующий активности деградации углеводного материала, и его применение
PH12015500284A1 (en) Interleukin-10 fusion proteins and uses thereof
EA201300058A1 (ru) Полипептид, обладающий бета-глюкозидазной активностью, и его применение
WO2010136549A3 (en) Modified aav capsid polypeptides
BR112012033699A2 (pt) polipeptídeo tendo atividade beta-glicosidase e seus usos
WO2014172541A3 (en) Engineered phenylalanine ammonia lyase polypeptides
EA201300056A1 (ru) Полипептид с активностью ацетилксиланэстеразы и его применения
EP4276180A3 (en) Clostridium histolyticum enzyme
EA201590162A1 (ru) МУТАНТНЫЕ ФРАГМЕНТЫ OspA И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И ПРИМЕНЕНИЕ
MX2019009222A (es) Neurotoxinas recombinantes de clostridium botulinum.
WO2015031726A3 (en) Engineered primate l-methioninase for therapeutic purposes
EA201491784A1 (ru) Антитела против лигандов рецептора в1 брадикинина

Legal Events

Date Code Title Description
FG Grant or registration